Founded in Menlo Park, California, Geron Corporation is a clinical-stage biopharmaceutical company dedicated to extending and enhancing patients' lives. The company's core mission is to develop innovative treatments for hematologic malignancies. Geron's primary product is imetelstat, a telomerase inhibitor designed to treat various myeloid malignancies. The organization focuses on addressing unmet medical needs within the hematology market.
Geron has garnered attention from notable investors and industry experts due to its pioneering approach in telomerase inhibition. Key achievements include advancing imetelstat through multiple clinical trials, demonstrating promising results in treating specific blood cancers. The company's impact is significant in the biopharmaceutical field, as it continues to push the boundaries of cancer treatment and improve patient outcomes.
